RXST · RxSight, Inc.
$6.89
-0.12 (-1.71%)
At close · Aug 14
Market Cap
$286.58M
Shares
41.59M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.89
Open$7.04
Day$6.87–7.10
52W close$4.59–13.09
Avg vol 30d1.0M
Short int4.1M · 9.8% float · 4.0d
Short vol46%
Last earningsAug 5, 2026
DataJul 2021–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 15, 2026
Est · unconfirmed
· in 13 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−11%
below
Price vs 50-day avg
+25%
above
RSI (14)
67
neutral
MACD trend
Positive
52-week position
27%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+24%
trailing
6-month return
−22%
trailing
YTD return
−34%
this year
Relative strength
−36%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $8 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +24 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.75% of float · ▲ +5.6% MoM · 4.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
147 holders — mid 3-yr range
Squeeze score
70
high risk · 0–100
Fundamentals
Revenue growth
−4%
Y/Y
Gross margin
77%
expanding
EPS growth
−34%
Y/Y
Free cash flow
$-19.3M
Balance sheet
$19.9M
net cash
Quant / Vol
risk profile
Volatility
64%
annualized · 1-yr
Max drawdown
−65%
past year
ATR
5.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 6, 2026
2026 full-year revenue
· 2026 full-year
$140M – $160M
Sales
· 2026 full-year
$110M – $120M
Collaboration Agreement revenue
· 2026 full-year
$30M – $40M
Gross margin
· 2026 full-year
73% – 75%
Operating expense
· 2026 full-year
$150M – $160M
Prior guidance
period ended
· from the 8-K filed Jul 6, 2026
Total company revenue
· second quarter of 2026
$32M – $34M
Sales
· second quarter of 2026
$27M
Guided vs delivered
· last 2 settled
Revenue
full-year 2025
guided $125M – $130M
$134.48M
Beat +5.5%
Full-year revenue
2024 full year
guided $128M – $135M
$139.93M
Beat +6.4%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−11%
Bearish
Price vs 50-day avg
+25%
Bullish
RSI (14)
67
Neutral
MACD trend
Positive
Bullish
52-week position
27%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $8 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +24 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.75% of float · ▲ +5.6% MoM · 4.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
147 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5
Now $7 · 27%
Range high $13
vs 200-day avg -11%
vs 50-day avg +25%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted net loss non-GAAP | -$4.6M | second quarter of 2026 | — |
|
|
|||
| Light Adjustable Lens (LAL) units | 24,917 | Q2 2026 | — |
|
|
|||
| Light Delivery Devices (LDD) units | 12 | Q2 2026 | — |
| Light Delivery Devices (LDD) units sold | 11 | preliminary second quarter 2026 | — |
|
|
|||
| LAL procedures | -0.4% | Q1 2026 | — |
| LDD installed base | 1,154 | Q1 2026 | — |
| Light Delivery Devices (LDDs) sold | 20 | Q1 2026 | — |
| LAL unit sales | 109,615 | Year Ended December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RXST
this stock
RxSight, Inc.
|
$286.58M | -33.9% | -3.9% | — | 9.8% |
|
ABT
Abbott Laboratories
|
$193.78B | -11.2% | +5.7% | 31.2 | 1.3% |
|
SYK
Stryker Corp
|
$130.11B | -3.5% | +11.2% | 35.2 | 2.2% |
|
MDT
Medtronic plc
|
$116.83B | -5.0% | +8.4% | 24.5 | 1.4% |
|
BSX
Boston Scientific Corp
|
$75.11B | -45.6% | +12.5% | 21.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RXST | +10.1% | +24.1% | -22.2% | +14.6% | -33.9% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +9.7% | +19.7% | -35.9% | +10.7% | -47.7% |
Key facts
CIK
1111485
CUSIP
78349D107
13F (30d)
149 filings
144 filers
Visit website
Investor relations